Últimos Artículos de Diabetes, Obesity and Metabolism
- Antidiabetes Medication Initiation Trends in U.S. Adults with Cirrhosis and Type 2 Diabetes: A Nationwide Study
- Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
- High cereal fibre but not total fibre is associated with a lower risk of type 2 diabetes: Evidence from Melbourne Collaborative Cohort Study
- Advanced hybrid closed loop system use in elderly with type 1 diabetes: effectiveness and safety in a prospective, observational, one year follow‐up real‐world study
- Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulfonylurea and metformin: IVS study
- COVID‐19 associated ketosis and diabetic ketoacidosis: A rapid review
- Effect of gastric distension with concurrent small intestinal saline or glucose infusion on incretin hormone secretion in healthy individuals: A randomized, controlled, crossover study
- Safety and efficacy of sodium‐glucose co‐transporter‐2 inhibitors in patients with kidney transplantation and diabetes mellitus
- EFFICACY AND SAFETY OF BEXAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META‐ANALYSIS
- Ketone monoester increases circulating levels of LEAP2 and decreases appetite in healthy men
- Allometric body shape indices, type 2 diabetes and kidney function: A two‐sample Mendelian randomization study
- Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study
- Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study
- Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility
- Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system
- Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
- HbA1c trajectories over 3 years in people with type 2 diabetes starting second‐line glucose‐lowering therapy: The prospective global DISCOVER study
- Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion using continuous glucose monitoring: a prospective observational study
- Trends and cyclic variation in the incidence of childhood type 1 diabetes in two Italian regions over 33 years and during the COVID‐19 pandemic
- Real‐world impact of once‐weekly subcutaneous semaglutide after 2 years of follow‐up: Results from a nationwide observational study in people with type 2 diabetes